Oncolytics Biotech Inc.

NASDAQ•ONCY

CEO: Mr. Wayne F. Pisano M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2001-10-05

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

連絡先情報

322 11th Avenue SW, Suite 804, Calgary, AB, T2R 0C5, Canada

403-670-7377

www.oncolyticsbiotech.com

時価総額

$106.38M

PER (TTM)

-4.1

18.8

配当利回り

52週高値

$1.51

52週安値

$0.33

52週レンジ

62%

順位50Top 68.9%

3.1

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.10+16.67%

直近4四半期の推移

フリーCF

-$4.84M+36.88%

直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

R&D Spending Increased Research and development expenses rose to 21.6M CAD in 2024, reflecting increased investment in clinical pipeline development.

Cash Reserves Declined Cash and cash equivalents decreased to 15.9M CAD by December 31, 2024, down from 34.9M CAD previous year.

Positive Breast Cancer Data BRACELET-1 study showed conservative median OS estimate of 32.1 months for PTX + pelareorep combination therapy.

Equity Position Weakened Total shareholders' equity fell sharply to 5.98M CAD at year-end 2024 from 27.6M CAD in 2023.

リスク要因

Going Concern Doubt Substantial doubt exists regarding ability to remain a going concern over the next twelve months without new financing.

Nasdaq Listing Risk Received Nasdaq delinquency notice due to bid price below $1.00; compliance required by August 12, 2025.

Widening Net Loss Net loss increased to 31.7M CAD in 2024 compared to 27.8M CAD reported in the prior fiscal year.

Product Development Stage Candidate pelareorep remains in research and development stage, requiring substantial future capital for commercialization.

見通し

Future Financing Essential Additional financing through equity or collaborations is necessary to fund operations beyond the estimated third quarter of 2025 runway.

Advance Key Clinical Trials Primary strategy focuses on advancing HR+/HER2- mBC and PDAC programs toward registration-enabling clinical studies.

Seek Strategic Partnerships Anticipates entering strategic alliances to fund large international trials and expand commercialization capabilities post-approval.

Patent Portfolio Strength Relying on extensive patent portfolio covering pelareorep and formulations, with rights extending to at least the end of 2031.

同業比較

売上高 (TTM)

MGNX

$126.00M

-10.8%

AGEN

$106.83M

-33.4%

ZNTL

$26.87M

-33.8%

粗利益率 (最新四半期)

SRZN

100.0%

+0.0pp

OVID

87.1%

-12.9pp

MGNX

81.6%

+19.9pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ARMP	$385.91M	-8.2	70.3%	198.5%
CNTX	$286.66M	-11.2	-30.9%	0.2%
SRZN	$231.77M	-2.7	-4404.2%	7.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月1日

EPS:-$0.05

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし